NTLA logo

Intellia Therapeutics (NTLA) CAPEX

Annual CAPEX

$5.78 M
-$8.21 M-58.68%

December 31, 2024

Summary

Performance

1-Year Change

-58.68%

3-Year Change

-54.7%

5-Year Change

-14.95%

15-Year Change

-42.74%

NTLA CAPEX Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

59.23%
NTLA annual capital expenditures is higher than 59.23% of companies in Healthcare sector

High & Low

All-time High

$58.39 M
NTLA annual capital expenditures is currently -90.10% below its historical high of $58.39 million

3-Year Low

$5.78 M
NTLA annual capital expenditures is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
NTLA previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
NTLA next annual earnings announcement has not yet been scheduled

OtherNTLAcash flowmetrics:

Annual FCF

-$354.66 M
NTLA annual free cash flow is -$354.66 million

Annual CFO

-$348.88 M
NTLA annual cash flow from operations is -$348.88 million

Annual CFI

$125.57 M
NTLA annual cash flow from investing activities is $125.57 million

Annual CFF

$185.75 M
NTLA annual cash flow from financing activities is $185.75 million

Quarterly CAPEX

$981.00 K
-$298.00 K-23.30%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

-65.79%

5-Year Change

-61.86%

NTLA Quarterly CAPEX Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

54.84%
NTLA quarterly capital expenditures is higher than 54.84% of companies in Healthcare sector

High & Low

All-time High

$46.26 M
NTLA quarterly capital expenditures is currently -97.88% below its historical high of $46.26 million

3-Year Low

$981.00 K
NTLA quarterly capital expenditures is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
NTLA previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 9, 2025
NTLA next earnings announcement is scheduled for May 9, 2025

OtherNTLAcash flowmetrics:

Quarterly FCF

-$86.18 M
NTLA quarterly free cash flow is -$86.18 million

Quarterly CFO

-$85.19 M
NTLA quarterly cash flow from operations is -$85.19 million

Quarterly CFI

$151.56 M
NTLA quarterly cash flow from investing activities is $151.56 million

Quarterly CFF

$2.32 M
NTLA quarterly cash flow from financing activities is $2.32 million

TTM CAPEX

$5.78 M
-$539.00 K-8.53%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

-54.7%

5-Year Change

-14.95%

NTLA TTM CAPEX Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

55.28%
NTLA TTM capital expenditures is higher than 55.28% of companies in Healthcare sector

High & Low

All-time High

$58.39 M
NTLA TTM capital expenditures is currently -90.10% below its historical high of $58.39 million

3-Year Low

$5.78 M
NTLA TTM capital expenditures is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
NTLA previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 9, 2025
NTLA next earnings announcement is scheduled for May 9, 2025

OtherNTLAcash flowmetrics:

TTM FCF

-$354.66 M
NTLA TTM free cash flow is -$354.66 million

TTM CFO

-$348.88 M
NTLA TTM cash flow from operations is -$348.88 million

TTM CFI

$125.57 M
NTLA TTM cash flow from investing activities is $125.57 million

TTM CFF

$185.75 M
NTLA TTM cash flow from financing activities is $185.75 million

NTLA CAPEX Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-58.7%0.0%0.0%
3 y3 years-54.7%-65.8%-54.7%
5 y5 years-14.9%-61.9%-14.9%

NTLA CAPEX Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-90.1%at low-97.9%at low-90.1%at low
5 y5-year-90.1%+61.2%-97.9%+40.5%-90.1%+61.2%
alltimeall time-90.1%+126.2%-97.9%+90.1%-90.1%+1019.8%

Intellia Therapeutics CAPEX History

DateAnnualQuarterlyTTM
Dec 2024
$5.78 M(-58.7%)
$981.00 K(-23.3%)
$5.78 M(-8.5%)
Sep 2024
-
$1.28 M(+26.4%)
$6.32 M(-32.6%)
Jun 2024
-
$1.01 M(-59.6%)
$9.37 M(-26.0%)
Mar 2024
-
$2.51 M(+64.9%)
$12.66 M(-9.5%)
Dec 2023
$13.98 M(-76.0%)
$1.52 M(-64.9%)
$13.98 M(-14.6%)
Sep 2023
-
$4.33 M(+0.7%)
$16.38 M(+0.6%)
Jun 2023
-
$4.30 M(+12.2%)
$16.28 M(+2.0%)
Mar 2023
-
$3.83 M(-2.0%)
$15.96 M(-72.7%)
Dec 2022
$58.39 M(+357.7%)
$3.91 M(-7.7%)
$58.39 M(+1.8%)
Sep 2022
-
$4.24 M(+6.5%)
$57.35 M(-0.5%)
Jun 2022
-
$3.98 M(-91.4%)
$57.65 M(+1.8%)
Mar 2022
-
$46.26 M(+1513.0%)
$56.60 M(+343.8%)
Dec 2021
$12.76 M(+255.8%)
$2.87 M(-36.8%)
$12.76 M(+17.1%)
Sep 2021
-
$4.54 M(+54.5%)
$10.89 M(+54.4%)
Jun 2021
-
$2.94 M(+21.8%)
$7.05 M(+36.9%)
Mar 2021
-
$2.41 M(+139.8%)
$5.15 M(+43.7%)
Dec 2020
$3.58 M(-47.2%)
$1.01 M(+44.1%)
$3.58 M(-30.4%)
Sep 2020
-
$698.00 K(-32.6%)
$5.15 M(-16.9%)
Jun 2020
-
$1.04 M(+22.6%)
$6.20 M(+1.6%)
Mar 2020
-
$845.00 K(-67.1%)
$6.11 M(-10.1%)
DateAnnualQuarterlyTTM
Dec 2019
$6.79 M(+6.9%)
$2.57 M(+47.1%)
$6.79 M(+16.9%)
Sep 2019
-
$1.75 M(+85.8%)
$5.81 M(-4.4%)
Jun 2019
-
$941.00 K(-38.6%)
$6.08 M(+0.7%)
Mar 2019
-
$1.53 M(-3.7%)
$6.04 M(-5.0%)
Dec 2018
$6.36 M(-37.0%)
$1.59 M(-21.0%)
$6.36 M(-11.2%)
Sep 2018
-
$2.02 M(+124.0%)
$7.16 M(-3.3%)
Jun 2018
-
$900.00 K(-51.4%)
$7.41 M(-4.8%)
Mar 2018
-
$1.85 M(-22.8%)
$7.78 M(-22.9%)
Dec 2017
$10.09 M(+63.7%)
$2.40 M(+6.1%)
$10.09 M(-9.1%)
Sep 2017
-
$2.26 M(+77.7%)
$11.10 M(+17.5%)
Jun 2017
-
$1.27 M(-69.4%)
$9.44 M(+1.3%)
Mar 2017
-
$4.16 M(+22.2%)
$9.32 M(+51.2%)
Dec 2016
$6.17 M(+141.4%)
$3.40 M(+462.8%)
$6.17 M(+70.8%)
Sep 2016
-
$605.00 K(-47.3%)
$3.61 M(+0.1%)
Jun 2016
-
$1.15 M(+13.8%)
$3.61 M(+18.4%)
Mar 2016
-
$1.01 M(+18.7%)
$3.05 M(+19.3%)
Dec 2015
$2.55 M
$849.00 K(+41.0%)
$2.55 M(+49.8%)
Sep 2015
-
$602.00 K(+2.6%)
$1.71 M(+54.6%)
Jun 2015
-
$587.00 K(+13.8%)
$1.10 M(+113.8%)
Mar 2015
-
$516.00 K
$516.00 K

FAQ

  • What is Intellia Therapeutics annual capital expenditures?
  • What is the all time high annual CAPEX for Intellia Therapeutics?
  • What is Intellia Therapeutics annual CAPEX year-on-year change?
  • What is Intellia Therapeutics quarterly capital expenditures?
  • What is the all time high quarterly CAPEX for Intellia Therapeutics?
  • What is Intellia Therapeutics quarterly CAPEX year-on-year change?
  • What is Intellia Therapeutics TTM capital expenditures?
  • What is the all time high TTM CAPEX for Intellia Therapeutics?
  • What is Intellia Therapeutics TTM CAPEX year-on-year change?

What is Intellia Therapeutics annual capital expenditures?

The current annual CAPEX of NTLA is $5.78 M

What is the all time high annual CAPEX for Intellia Therapeutics?

Intellia Therapeutics all-time high annual capital expenditures is $58.39 M

What is Intellia Therapeutics annual CAPEX year-on-year change?

Over the past year, NTLA annual capital expenditures has changed by -$8.21 M (-58.68%)

What is Intellia Therapeutics quarterly capital expenditures?

The current quarterly CAPEX of NTLA is $981.00 K

What is the all time high quarterly CAPEX for Intellia Therapeutics?

Intellia Therapeutics all-time high quarterly capital expenditures is $46.26 M

What is Intellia Therapeutics quarterly CAPEX year-on-year change?

Over the past year, NTLA quarterly capital expenditures has changed by $0.00 (0.00%)

What is Intellia Therapeutics TTM capital expenditures?

The current TTM CAPEX of NTLA is $5.78 M

What is the all time high TTM CAPEX for Intellia Therapeutics?

Intellia Therapeutics all-time high TTM capital expenditures is $58.39 M

What is Intellia Therapeutics TTM CAPEX year-on-year change?

Over the past year, NTLA TTM capital expenditures has changed by $0.00 (0.00%)